These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 19380217

  • 1. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
    Richards TM, Plowman PN, Reznek R, Ball SA.
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
    [No Abstract] [Full Text] [Related]

  • 2. Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
    Verzoni E, Lanocita R, Procopio G.
    Clin Genitourin Cancer; 2012 Jun; 10(2):130-3. PubMed ID: 22226825
    [No Abstract] [Full Text] [Related]

  • 3. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
    Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H.
    Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
    [Abstract] [Full Text] [Related]

  • 4. Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.
    Di Lorenzo G, Autorino R.
    J Urol; 2010 Feb; 183(2):824-5; author reply 825. PubMed ID: 20022057
    [No Abstract] [Full Text] [Related]

  • 5. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
    Ravaud A, Digue L, Trufflandier N, Smith D.
    Ann Oncol; 2010 Feb; 21(2):431-432. PubMed ID: 19945958
    [No Abstract] [Full Text] [Related]

  • 6. [Targeted therapy - point blank or single shot].
    Rübben H.
    Urologe A; 2008 Oct; 47(10):1297. PubMed ID: 18682912
    [No Abstract] [Full Text] [Related]

  • 7. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 8. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
    Herrmann E, Marschner N, Grimm MO, Ohlmann CH, Hutzschenreuter U, Overkamp F, Groschek M, Blumenstengel K, Pühse G, Steiner T.
    World J Urol; 2011 Jun; 29(3):361-6. PubMed ID: 21461939
    [Abstract] [Full Text] [Related]

  • 9. Sequential sorafenib and sunitinib for renal cell carcinoma.
    Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J, Escudier B.
    J Urol; 2009 Jul; 182(1):29-34; discussion 34. PubMed ID: 19447417
    [Abstract] [Full Text] [Related]

  • 10. Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
    Yuasa T, Urakami S, Yamamoto S, Yonese J, Nakano K, Kodaira M, Takahashi S, Hatake K, Inamura K, Ishikwa Y, Fukui I.
    Urology; 2011 Apr; 77(4):831-5. PubMed ID: 21316083
    [Abstract] [Full Text] [Related]

  • 11. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.
    Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C.
    Cancer; 2009 Jan 01; 115(1):61-7. PubMed ID: 19051290
    [Abstract] [Full Text] [Related]

  • 12. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
    Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E.
    BJU Int; 2011 Oct 01; 108(8 Pt 2):E250-7. PubMed ID: 21599821
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
    Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B.
    J Clin Oncol; 2008 Jan 01; 26(1):127-31. PubMed ID: 18165647
    [Abstract] [Full Text] [Related]

  • 14. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K, Bergmann L, Albers P, Gschwend J, Jäger E, Keilholz U.
    Aktuelle Urol; 2010 May 01; 41(3):193-6. PubMed ID: 20486036
    [Abstract] [Full Text] [Related]

  • 15. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
    Miller K, Bergmann L, Albers P, Jäger E, Jakse G, Geschwend JE, Marschner N.
    Aktuelle Urol; 2007 Jul 01; 38(4):328-30. PubMed ID: 17647172
    [Abstract] [Full Text] [Related]

  • 16. Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Bamias A.
    Eur Urol; 2009 Jun 01; 55(6):1439. PubMed ID: 18950935
    [No Abstract] [Full Text] [Related]

  • 17. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, Keilholz U.
    Oncology; 2009 Jun 01; 76(5):350-4. PubMed ID: 19321976
    [Abstract] [Full Text] [Related]

  • 18. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
    Masini C, Sabbatini R, Porta C, Procopio G, Di Lorenzo G, Onofri A, Buti S, Iacovelli R, Invernizzi R, Moscetti L, Aste MG, Pagano M, Grosso F, Lucia Manenti A, Ortega C, Cosmai L, Del Giovane C, Conte PF.
    BJU Int; 2012 Sep 01; 110(5):692-8. PubMed ID: 22364110
    [Abstract] [Full Text] [Related]

  • 19. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K, Bergmann L, Jäger E, Jakse G, Wirth M, Keilholz U, interdisziplinäre Arbeitsgruppe Nierenzellkarzinom der Deutschen Krebsgesellschaft e.V. (DKG).
    Aktuelle Urol; 2009 Jan 01; 40(1):27-30. PubMed ID: 19177318
    [Abstract] [Full Text] [Related]

  • 20. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.
    Br J Dermatol; 2009 Nov 01; 161(5):1045-51. PubMed ID: 19558553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.